As researchers embrace more complex cellular models, high-content analysis brings new opportunities and challenges to drug discovery.

Welcome to the Weekly Rundown where the DDN editors cover this week’s top biotech and pharma news.

Twenty years ago, drug discovery ran on a simple script of screening compounds and hoping for a hit. This exclusive ebook, ...

Alzheimer’s disease often overlaps with other causes of cognitive decline. A new proteomics project aims to untangle that ...

Traditional animal models remain an important part of preclinical research, but species differences can limit translation of ...

From AI agents to cell therapy to Alzheimer’s drug pipelines, this issue follows the same problem across three fields:what it takes to turn something that works once into something that works at scale ...

Priyom Bose earned her Ph.D. in Plant Biology and Biotechnology from the University of Madras, India, in 2019 before ...

Antibody discovery is becoming less about finding the strongest binder and more about finding molecules that can survive the journey to the clinic.

A win for autoimmune disease, a set back for Alzheimer’s disease, an FDA backing for a multi-cancer blood test, and more led the news this week.

Mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome Type A, progressively destroys cognitive and motor function in early childhood through a single missing enzyme: ...

Cambridge, UK, 27 July 2026: Novogene Europe, a multiomics research services partner, today announced that it has expanded its single-cell RNA sequencing capability at its Cambridge Omics Centre. This ...

Ask five regulatory affairs professionals where things stand with the FDA, the EMA and the ICH on artificial intelligence (AI), and it would not be surprising to get five different, partially ...